Biotx.ai Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
15
Biotx.ai General Information
Description
Developer of a drug discovery platform designed to identify significant patterns for developing novel diagnostics and therapies. The company's platform effectively monitors individual responses like artificial neural networks to stratify patients in clinical studies and develop new drugs, enabling physicians to overcome unmet medical needs.
Contact Information
Website
www.biotx.aiCorporate Office
- Am Mühlenberg 11
- 14476 Potsdam
- Germany
Corporate Office
- Am Mühlenberg 11
- 14476 Potsdam
- Germany
Biotx.ai Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 10. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 9. Later Stage VC | 01-Jun-2020 | Completed | Pre-Clinical Trials | |||
| 8. Later Stage VC | 01-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 7. Accelerator/Incubator | 01-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 6. Accelerator/Incubator | 20-Mar-2018 | Completed | Pre-Clinical Trials | |||
| 5. Accelerator/Incubator | 01-Jan-2018 | Completed | Startup | |||
| 4. Accelerator/Incubator | 21-Jul-2017 | Completed | Startup | |||
| 3. Grant | 09-Jul-2015 | Completed | Startup | |||
| 2. Angel (individual) | Completed | Startup |
Biotx.ai Patents
Biotx.ai Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022162122-A1 | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection | Inactive | 29-Jan-2021 | ||
| EP-3790994-A1 | Method for predicting the risk of late-onset alzheimer's diseases | Inactive | 07-May-2018 | ||
| US-20210230696-A1 | Method for predicting the risk of late-onset alzheimer's diseases | Inactive | 07-May-2018 | ||
| WO-2019215085-A1 | Method for predicting the risk of late-onset alzheimer's diseases | Inactive | 07-May-2018 | C12Q1/6883 |
Biotx.ai Signals
Biotx.ai Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ocama Partners | Family Office | Minority | ||
| Oxonian Ventures | Venture Capital | Minority | ||
| Ruppiner Kliniken | Corporation | Minority | ||
| Hoxton Ventures | Venture Capital | Minority | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | Minority |
Biotx.ai FAQs
-
When was Biotx.ai founded?
Biotx.ai was founded in 2014.
-
Where is Biotx.ai headquartered?
Biotx.ai is headquartered in Potsdam, Germany.
-
What is the size of Biotx.ai?
Biotx.ai has 13 total employees.
-
What industry is Biotx.ai in?
Biotx.ai’s primary industry is Discovery Tools (Healthcare).
-
Is Biotx.ai a private or public company?
Biotx.ai is a Private company.
-
What is Biotx.ai’s current revenue?
The current revenue for Biotx.ai is .
-
How much funding has Biotx.ai raised over time?
Biotx.ai has raised $2.26M.
-
Who are Biotx.ai’s investors?
Ocama Partners, Oxonian Ventures, Ruppiner Kliniken, Hoxton Ventures, and Johnson & Johnson Innovation - JLABS are 5 of 15 investors who have invested in Biotx.ai.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process